Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00379067
Status:
COMPLETED
Last Update Posted:
2014-10-10
First Post:
2006-09-19
Brief Title:
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 04 mg Tablets Once Daily on Nocturia Compared to Placebo in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Randomized double-blind placebo-controlled study with two treatment arms Tamsulosin OCAS 04 mg placebo The study comprises a 2-week placebo run-in followed by a 12-week treatment period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None